Study S002297

An Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exendin-4 (Exenatide) in the Treatment of Patients With Moderate Severity Parkinson's Disease.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01174810
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: UNKNOWN
Enrollment: 40
Start: 2010-07
Primary completion: 2013-03
Lead sponsor: University College, London
Conditions: Parkinson's Disease
Interventions: DRUG:Exenatide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2009-018137-37; NIH:2009

Registered primary outcomes

Change from baseline to 12 months & 14 months between patients on active Exenatide treatment and PD controls in respect of their UPDRS-off-medication motor subscore. []

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026610	Exenatide and the treatment of patients with Parkinson's disease. Aviles-Olmos I, The Journal of clinical investigation	2013	Randomized trial	PMID 23728174 DOI	cites ClinicalTrials.gov:NCT01174810; registry reference DERIVED:23728174